FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and…
Read More...
Read More...
